esophageal cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1)Patients who are male or female aged 20 years or more at the time of informed consent. 2)Patients who are willing to supply the tumor tissue 3)Patients with esophagus squamous cell carcinoma or adenocarcinoma histologically 4)HLA-A*24:02-positive patients 5)The patient who can initiate the administration of the test drug more than 30 days before the esophagus resection
Exclusion criteria
Exclusion criteria: 1)The patient who are going to receive or received the following treatment for the primary disease /Antineoplastic drug /Radiotherapy /Thermotherapy /Systemic immunosuppressant /immunotherapy 2)Patients with uncontrolled systemic or active infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor-infiltrating CD8-positive lymphocytes | — |
Secondary
| Measure | Time frame |
|---|---|
| Cytotoxic T cell | — |
Countries
Japan
Contacts
Shionogi & Co., Ltd. Corporate Communications Department